147 related articles for article (PubMed ID: 35657991)
1. Healthcare resource utilization and medical costs in patients with terminal cancer during best supportive care.
Kang DW; Shim YB; Lee EK; Park MH
PLoS One; 2022; 17(6):e0269565. PubMed ID: 35657991
[TBL] [Abstract][Full Text] [Related]
2. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
3. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
5. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
6. Population-Based Estimates of Health Care Utilization and Expenditures by Adults During the Last 2 Years of Life in Canada's Single-Payer Health System.
Rosella LC; Kornas K; Bornbaum C; Huang A; Watson T; Shuldiner J; Wodchis WP
JAMA Netw Open; 2020 Apr; 3(4):e201917. PubMed ID: 32236531
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA.
Deitelzweig SB; Lovelace B; Christoph M; Lingohr-Smith M; Lin J; Fermann GJ
Adv Ther; 2020 Sep; 37(9):3942-3953. PubMed ID: 32699994
[TBL] [Abstract][Full Text] [Related]
9. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
10. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
11. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
12. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims.
Sacks NC; Healey BE; Cyr PL; Slocomb T; James E; Beggs AH; Graham RJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1019-1026. PubMed ID: 33843254
[No Abstract] [Full Text] [Related]
13. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
15. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
17. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
[TBL] [Abstract][Full Text] [Related]
18. Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China.
Yin X; Xu Y; Man X; Liu L; Jiang Y; Zhao L; Cheng W
Cancer Med; 2019 Jun; 8(6):3250-3260. PubMed ID: 31062522
[TBL] [Abstract][Full Text] [Related]
19. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.
Ihbe-Heffinger A; Ehlken B; Bernard R; Berger K; Peschel C; Eichler HG; Deuson R; Thödtmann J; Lordick F
Ann Oncol; 2004 Mar; 15(3):526-36. PubMed ID: 14998860
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
